Levocarnitine for use in the Treatment of Carnitine Deficiency in ESRD Patients — NCD 159 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 159 governing levocarnitine coverage for ESRD patients, with an effective date of March 7, 2026. Here's what changes for billing teams.

CMS levocarnitine coverage policy under NCD 159 in the Medicare system sets strict medical necessity thresholds for intravenous levocarnitine in end-stage renal disease patients. This policy does not list specific CPT or HCPCS codes in the current documentation — but the coverage criteria are detailed and unforgiving. If your facility bills levocarnitine for dialysis patients, the documentation requirements alone make this a high-risk claim category.

Quick-Reference Table

CMS Levocarnitine Coverage Criteria and Medical Necessity Requirements 2026

The CMS levocarnitine coverage policy under NCD 159 covers intravenous levocarnitine for ESRD patients — but only under two specific clinical conditions. Both require documented carnitine deficiency, defined as a plasma free carnitine level below 40 micromol/L. That threshold is non-negotiable in the policy text.

The patient must also have been on dialysis for a minimum of three months before levocarnitine becomes eligible for Medicare reimbursement. This is a hard stop. Claims submitted for patients with less than three months of dialysis history will not pass medical necessity review.

Once the minimum dialysis duration is met and carnitine deficiency is confirmed, the patient must present with one of two clinical syndromes:

1. Erythropoietin-resistant anemia. The patient must have a persistent hematocrit below 30% while on erythropoietin treatment. That treatment must be at the dosage considered clinically appropriate for the patient — not a reduced or trial dose. Iron replacement must have been tried. Other causes of anemia must have been investigated and treated. CMS is looking for a diagnosis of exclusion here, and your documentation needs to show that work was done.

2. Intradialytic hypotension. The patient must experience hypotension during hemodialysis that interferes with completing the intended dialysis session. Standard fluid management and other usual measures must have already been applied. The hypotension must have occurred in at least two separate dialysis treatments within a single 30-day period. One episode is not enough — this requires a documented pattern.

These aren't soft guidelines. They are the coverage criteria. If your patient doesn't meet both the plasma free carnitine threshold and one of these two indications, Medicare will not pay. Prior authorization is not explicitly required in the NCD text, but documentation of medical necessity is extensive enough that you should treat every claim as if it will be audited. Build the file before you bill.

The policy also contains a hard 6-month response requirement. If the patient does not show measurable improvement within six months of starting levocarnitine, continued treatment is no longer covered. Your billing team should track initiation dates and flag accounts approaching that window.

CMS Levocarnitine Exclusions and Non-Covered Indications

CMS is direct about this: all other indications for levocarnitine in the ESRD population are non-covered. The policy doesn't leave room for clinical judgment on off-label uses. If the indication isn't erythropoietin-resistant anemia or intradialytic hypotension, the claim will be denied.

Oral levocarnitine is also not addressed as a covered service under this NCD. The policy specifically addresses intravenous administration. Billing for oral formulations under this NCD would be inappropriate.

The 6-month non-response exclusion is worth calling out separately. It's not just a coverage limitation — it's a mandatory documentation checkpoint. If you continue billing levocarnitine past six months without documented clinical improvement in the medical record, you're billing a non-covered service. That's a claim denial risk and a compliance exposure.

Coverage Indications at a Glance

CMS Levocarnitine Billing Guidelines and Action Items 2026

The real issue with NCD 159 is not the coverage criteria themselves — it's whether your documentation actually supports those criteria at the time of billing. Here's what your team needs to do before March 7, 2026.

CPT, HCPCS, and ICD-10 Codes for Levocarnitine Under NCD 159

Covered HCPCS/CPT Codes

The current NCD 159 policy document does not list specific CPT or HCPCS codes. This is a known gap in the published policy data. Levocarnitine billing typically uses HCPCS codes assigned at the Medicare Administrative Contractor or claims processing level, but those codes are not enumerated in this NCD.

Contact your Medicare Administrative Contractor for the current applicable HCPCS codes for intravenous levocarnitine before billing under this updated policy. MAC-level billing guidelines may also apply alongside this NCD.

Key ICD-10-CM Diagnosis Codes

The policy document does not list specific ICD-10-CM codes. Your diagnosis coding should reflect the covered indication — erythropoietin-resistant anemia or intradialytic hypotension — along with ESRD and carnitine deficiency. Work with your coding team to confirm the appropriate ICD-10 codes for each patient's specific clinical picture.